Gupta Shalabh K. 4

What Happened
Shalabh K. Gupta, CEO and director of Unicycive Therapeutics (UNCY), was granted 762,200 restricted stock units (RSUs) on 2026-05-14. The Form 4 reports this as an award (code A) with a reported price of $0.00 per share (a derivative award payable in common stock). This is a compensation grant, not a purchase or sale.

Key Details

• Transaction date: 2026-05-14; Form 4 filed: 2026-05-21 (filed after the typical 2-business-day window).
• Transaction type/code: Grant/Award (A); derivative RSU award.
• Shares/units: 762,200 RSUs; reported price $0.00.
• Vesting: RSUs vest 1/3 on each anniversary of the grant date for 3 years, subject to continued service (per footnote F1).
• Shares owned after transaction: Not disclosed in the provided filing.
• Filing timeliness: Filed 7 days after the transaction date (late relative to the usual 2-business-day Form 4 requirement).

Context
RSUs are a form of compensation that convert to common stock only as they vest; no shares were exchanged or sold at grant. Because this is an award rather than an open-market purchase, it primarily reflects compensation, not an immediate insider buy/sell signal. Retail investors should note the vesting schedule—shares become real ownership over three years—and that later sales of vested shares would appear in subsequent filings.